Celtaxsys is a clinical-stage pharmaceutical development company focused on advancing novel foundational therapies to treat inflammation in rare, orphan designated diseases. The company's flagship investigational medicine, oral once daily acebilustat, is aimed at preserving lung function in cystic fibrosis (CF) by specifically modulating key aspects of a dysregulated (i.e. over-activated) immune response.
Celtaxsys has filed 24 patents.
Clusters of differentiation, Immunology, G protein coupled receptors, Immune system, Eicosanoids
Clusters of differentiation, Immunology, G protein coupled receptors, Immune system, Eicosanoids
Latest Celtaxsys News
Nov 5, 2018
LIFESTYLE DRUGS Market Lifestyle drug is an term commonly applied to medications which treat non-life-threatening and non-painful conditions such as baldness, wrinkles, erectile dysfunction, or acne, which the speaker perceives as either not medical problems at all or as minor medical conditions relative to others. Proponents point out that improving the patient’s subjective quality of life has always been a primary concern of medicine. There is direct impact of lifestyle drugs on society, particularly in the developing world. Implications associated with labeling of indications and products sales of these lifestyle drugs may be varied. Drugs can, over time, switch from ‘lifestyle’ to ‘mainstream’ use. Lifestyle Drugs is also used in adults and children to treat Crohn’s disease or juvenile idiopathic arthritis. Global Lifestyle Drugs Market 2018-2023, has been prepared on the basis of an in-depth market analysis with from industry experts. The report also includes a debate of the leading players working in this market. In order to calculate the Lifestyle Drugs market size, the report considers the revenue generated from services provided to end-users such as the pharmaceutical and healthcare companies, medical device manufacturers, contract research organizations, biotechnology companies, and academic and research institutes. Request for Sample report at: https://www.reportsweb.com/inquiry&RW00012270377/sample The market research report on the Global Lifestyle Drugs Market by Reports Web is a prominent part of the pharmaceutical and healthcare portfolio and offers insights into the leading trends in the market and potential drivers, including the growth of the Global Lifestyle Drugs Market Industry. The report undergoes a detailed procedure of data collection methodology and presents an in-depth analysis of all the market segments and sub-segments. Any Query or Specific Discount Requirement? Ask our Industry Expert @ https://www.reportsweb.com/inquiry&RW00012270377/discount Some of the major players operating in the Global Lifestyle Drugs Market include: Allergan, BMS, Eli Lilly, Pfizer, Acerus Pharmaceuticals, Alkermes, Amorepacific, AndroScience, Anterios, AstraZeneca, Avanir Pharmaceuticals, Avolynt, Celtaxsys, Cerecor, Corcept Therapeutics, Cosmo Pharmaceuticals, CTC Bio, Dermira, Dong-A ST, Euthymics Bioscience, Foamix, Follicum, Forendo Pharma, Futura Medical Developments, Galderma, Lifestyle Drugs Market: Product Segment Analysis: Depression, Dermatology, Sexual dysfunction, Obesity, Lifestyle Drugs Market: Application Segment Analysis Children, Adults, Senior Citizens, Competitive Landscape: Global Lifestyle Drugs Market The Global Lifestyle Drugs Market is highly fragmented and is based on new product launches, product advances, and clinical results of products. Therefore, the leading competitors have made use of different strategies, including new product launches, product advances, clinical trials, assumptions and methodologies, high investments on R&D, market initiatives, joint ventures, mergers & acquisitions, agreements, partnerships, and collaborations, to increase their presence in the market. What the report offers: Market Definition, including the product definition and the identification of key drivers and restraints for the market. Market analysis for the Global Lifestyle Drugs Market, with region-specific assessment and competitive landscape on a global and regional basis. Different factors that are instrumental in changing the market situations, emerging growth opportunities, and identification of key companies, which can affect the market on a global and regional scale. Thoroughly researched competitive scenario with the profiles of leading competitors along with their strategic initiatives and market shares. Identification and analysis of the macro and micro factors that affect the Global Lifestyle Drugs Market on both global and regional scale. A complete list of major market participants, including the analysis of their present strategies, investments, and key financial data. Access Full Report Description, TOC and Table of Figure @ https://www.reportsweb.com/inquiry&RW00012270377/buying The research report studies the market landscape and its growth prospects during the forecast period. Several research tools such as Porter’s five forces analysis, SWOT analysis, and so on. Have been exercised to provide a precise understanding of the overall market. The market research report provides an in-depth analysis of the major trends and technologies that are playing an important role in the growth of the market over the coming years. The study provides a detailed assessment of Global Lifestyle Drugs Market, in terms of revenue, throughout the aforementioned period. About ReportsWeb: ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries. Contact Us:
Celtaxsys Frequently Asked Questions (FAQ)
Where is Celtaxsys's headquarters?
Celtaxsys's headquarters is located at 201 17th Street, Atlanta.
What is Celtaxsys's latest funding round?
Celtaxsys's latest funding round is Series E.
How much did Celtaxsys raise?
Celtaxsys raised a total of $52.7M.
Who are the investors of Celtaxsys?
Investors of Celtaxsys include Lumira Ventures, Domain Associates, Masters Capital Management, Georgia Research Alliance, RMI Partners and 6 more.
Who are Celtaxsys's competitors?
Competitors of Celtaxsys include PDS Biotechnology, Keryx Biopharmaceuticals, Larimar Therapeutics, Versartis, VLST Corporation and 7 more.
Compare Celtaxsys to Competitors
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.
LeukoSight Inc. is an early stage biotechnology company developing a line of therapeutics that can be used to treat autoimmune and inflammatory diseases.
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.
CellXplore is a new, biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.nThe company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.nCellXplore's platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer's disease, Parkinson's disease and inflammatory diseases.
Osprey Pharmaceuticals is a privately held biotechnology company focused on developing and commercializing a first-in-class family of therapeutic proteins (Leukocyte Population Modulators) capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The company's proprietary LPMs selectively and systematically destroy disease-related leukocytes by infiltrating the chemokine system that regulates the movement and activity of leukocytes.
XOMA is a biotech royalty aggregator in the biotechnology industry. The company's main service is acquiring the economic rights to future milestone and royalty payments associated with partnered pre-commercial clinical candidates, providing non-dilutive, non-recourse funding to the sellers. XOMA primarily sells to the biotech and pharmaceutical industries. It was founded in 1981 and is based in Berkeley, California.